文献速递前列腺癌

欧洲泌尿外科学会2018年立场:原发性局限性前列腺癌的局灶治疗

Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018.
PubMed 文献 · Eur Urol · 2018-01-17

欧洲泌尿外科学会(EAU)2018年立场文件指出,局限性前列腺癌的根治性治疗对许多男性属于过度治疗,局灶消融治疗应用快速增加,但生物学和实际担忧仍存,尚未被证明为可靠治疗选择。多数研究针对低危疾病且随访不成熟,作者认为局灶治疗应视为研究性模式。

要点

  • 前列腺癌的多灶性特征不支持单灶治疗,影像学限制可能妨碍准确识别癌灶数目、位置和范围。
  • 多数局灶消融系列针对低危疾病,随访不成熟且缺乏一致随访,再治疗并发症常未考虑。
  • 作者认为局灶治疗为研究性模式,鼓励前瞻性记录结局并招募合适患者。

核心结论

  • 局灶治疗应被视为研究性模式,尚未被证明为可靠的局限性前列腺癌治疗选择。

研究设计与样本

  • 欧洲泌尿外科学会(EAU)2018年立场文件,基于现有文献和专家观点。

主要发现

  • 前列腺癌的多灶性特征不支持单灶治疗,影像学限制可能妨碍准确识别癌灶数目、位置和范围。
  • 多种消融选项报告的结果主要针对低危疾病,多数系列相对不成熟且缺乏一致随访,再治疗并发症常未考虑。

临床怎么用

  • 作者鼓励前瞻性记录局灶治疗结局并招募合适患者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Radical treatment of localised prostate cancer is recognised to be an unnecessary intervention or overtreatment in many men. Consequently, there has been a rapid uptake in the use of focal ablative therapies. However, there are several biological and practical concerns about such approaches as they have yet to be proved as robust treatment options. In particular, the multifocal nature of prostate cancer argues against unifocal treatment, while limitations in imaging can preclude the accurate identification of the number, location, and extent of prostate cancer foci. To date, a number of ablative options have reported results on mainly low-risk disease. Most series are relatively immature, with a lack of consistent follow-up, and the morbidity of retreatment is often not considered. The authors consider focal therapy to be an investigational modality, and encourage prospective recording of outcomes and recruitment of suitable patients. PATIENT SUMMARY: Focal therapy of prostate cancer is the targeted destruction of cancer within a specific part of the prostate gland, sparing the rest of the prostate and nearby tissue. This procedure could potentially reduce side effects when compared with established standard treatments, such as surgery or radiotherapy, which treat the entire prostate. Studies show that for most men with low-risk cancer, active surveillance is the preferred treatment option. However, the available data regarding all forms of focal therapy are still poor and inconclusive. Consequently, due to both the lack of clear results associated with focal therapy and the difficulties in detecting all cancerous areas of the prostate, focal therapy should be considered an investigational modality only.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. van der Poel HG, van den Bergh RCN, Briers E, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol. 2018. PMID: 29373215. doi:10.1016/j.eururo.2018.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。